BRIEF-Kalaris Therapeutics Reports Positive Initial Phase 1A Data For Th103

Reuters

Dec 18, 2025

BRIEF-Kalaris <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Reports Positive Initial Phase 1A Data For Th103

Dec 17 (Reuters) - Kalaris Therapeutics Inc KLRS.O:

KALARIS THERAPEUTICS REPORTS POSITIVE INITIAL PHASE 1A DATA FOR TH103 IN TREATMENT-NAÏVE NEOVASCULAR AMD
KALARIS THERAPEUTICS INC - TH103 GENERALLY WELL TOLERATED, SUPPORTING FURTHER DOSE ESCALATION
KALARIS THERAPEUTICS INC - ACCELERATING ENROLLMENT IN PHASE 1B/2 STUDY; DATA EXPECTED 2H 2026
KALARIS THERAPEUTICS INC - TH103 SHOWED MEAN 10-LETTER GAIN IN VISUAL ACUITY AT MONTH 1

Source text: ID:nGNX6G773c

Further company coverage: KLRS.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2592943616"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2592943616\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2592943616?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-18 05:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2592943616","market":"fut","top_or_hot":-1,"title":"BRIEF-Kalaris Therapeutics Reports Positive Initial Phase 1A Data For Th103","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Kalaris <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Reports Positive Initial Phase 1A Data For Th103</title></head><body><p><span>Dec 17 (Reuters)</span><span> - </span>Kalaris Therapeutics Inc <span>KLRS.O</span>:</p><ul><li><p>KALARIS THERAPEUTICS REPORTS POSITIVE INITIAL PHASE 1A DATA FOR TH103 IN TREATMENT-NAÏVE NEOVASCULAR <a href=\"https://laohu8.com/S/AMD\">AMD</a></p></li><li><p>KALARIS THERAPEUTICS INC - TH103 GENERALLY WELL TOLERATED, SUPPORTING FURTHER DOSE ESCALATION</p></li><li><p>KALARIS THERAPEUTICS INC - ACCELERATING ENROLLMENT IN PHASE 1B/2 STUDY; DATA EXPECTED 2H 2026</p></li><li><p>KALARIS THERAPEUTICS INC - TH103 SHOWED MEAN 10-LETTER GAIN IN VISUAL ACUITY AT MONTH 1</p></li></ul><p>Source text: <span>ID:nGNX6G773c</span></p><p>Further company coverage: <span>KLRS.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Kalaris Therapeutics Reports Positive Initial Phase 1A Data For Th103</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Kalaris Therapeutics Reports Positive Initial Phase 1A Data For Th103\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-18 05:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Kalaris <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Reports Positive Initial Phase 1A Data For Th103</title></head><body><p><span>Dec 17 (Reuters)</span><span> - </span>Kalaris Therapeutics Inc <span>KLRS.O</span>:</p><ul><li><p>KALARIS THERAPEUTICS REPORTS POSITIVE INITIAL PHASE 1A DATA FOR TH103 IN TREATMENT-NAÏVE NEOVASCULAR <a href=\"https://laohu8.com/S/AMD\">AMD</a></p></li><li><p>KALARIS THERAPEUTICS INC - TH103 GENERALLY WELL TOLERATED, SUPPORTING FURTHER DOSE ESCALATION</p></li><li><p>KALARIS THERAPEUTICS INC - ACCELERATING ENROLLMENT IN PHASE 1B/2 STUDY; DATA EXPECTED 2H 2026</p></li><li><p>KALARIS THERAPEUTICS INC - TH103 SHOWED MEAN 10-LETTER GAIN IN VISUAL ACUITY AT MONTH 1</p></li></ul><p>Source text: <span>ID:nGNX6G773c</span></p><p>Further company coverage: <span>KLRS.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"KLRS","symbol_name":"Kalaris Therapeutics Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nFWN3XN18T:1","article_id":"2592943616","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2592943616","pubTimestamp":1766005444,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Kalaris Therapeutics Reports Positive Initial Phase 1A Data For Th103Dec 17 (Reuters) - Kalaris Therapeutics Inc KLRS.O:KALARIS THERAPEUTICS REPORTS POSITIVE INITIAL PHASE 1A DATA FOR TH103 IN T","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"KLRS":"Kalaris Therapeutics Inc.","BK4139":"生物科技"},"translate_title":"简介-Kalaris Therapeutics报告Th103的积极初始1A期数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KLRS":0.9},"content_text":"BRIEF-Kalaris Therapeutics Reports Positive Initial Phase 1A Data For Th103Dec 17 (Reuters) - Kalaris Therapeutics Inc KLRS.O:KALARIS THERAPEUTICS REPORTS POSITIVE INITIAL PHASE 1A DATA FOR TH103 IN TREATMENT-NAÏVE NEOVASCULAR AMDKALARIS THERAPEUTICS INC - TH103 GENERALLY WELL TOLERATED, SUPPORTING FURTHER DOSE ESCALATIONKALARIS THERAPEUTICS INC - ACCELERATING ENROLLMENT IN PHASE 1B/2 STUDY; DATA EXPECTED 2H 2026KALARIS THERAPEUTICS INC - TH103 SHOWED MEAN 10-LETTER GAIN IN VISUAL ACUITY AT MONTH 1Source text: ID:nGNX6G773cFurther company coverage: KLRS.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}